According to CTI BioPharma 's latest financial reports the company's current EPS (TTM) is -$0.58. In 2022 the company made an earnings per share (EPS) of -$0.85 an increase over its 2021 EPS that were of -$1.08.
Year | EPS | Change |
---|---|---|
2023 (TTM) | -$0.58 | -31.76% |
2022 | -$0.85 | -21.3% |
2021 | -$1.08 | 45.95% |
2020 | -$0.74 | 7.25% |
2019 | -$0.69 | 30.19% |
2018 | -$0.53 | -58.91% |
2017 | -$1.29 | -29.12% |
2016 | -$1.82 | -72.84% |
2015 | -$6.70 | 6.35% |
2014 | -$6.30 |
Company | EPS | EPS differencediff. | Country |
---|---|---|---|
Novartis NVS | $3.74 | -744.83% | ๐จ๐ญ Switzerland |
Eli Lilly LLY | $5.43 | -1,036.08% | ๐บ๐ธ USA |
Amgen AMGN | $14.15 | -2,539.66% | ๐บ๐ธ USA |
Baxter BAX | $5.12 | -982.76% | ๐บ๐ธ USA |
Incyte INCY | $1.90 | -427.59% | ๐บ๐ธ USA |
Bristol-Myers Squibb BMY | $3.97 | -784.48% | ๐บ๐ธ USA |
Teva Pharmaceutical Industries TEVA | -$2.00 | 244.83% | ๐ฎ๐ฑ Israel |